|
1
|
Meza R, Meernik C, Jeon J and Cote ML:
Lung cancer incidence trends by gender, race and histology in the
United States, 1973–2010. PLoS One. 10:e01213232015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Riaz SP, Lüchtenborg M, Coupland VH,
Spicer J, Peake MD and Møller H: Trends in incidence of small cell
lung cancer and all lung cancer. Lung Cancer. 75:280–284. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen Z, Fillmore CM, Hammerman PS, Kim CF
and Wong KK: Non-small-cell lung cancers: A heterogeneous set of
diseases. Nat Rev Cancer. 14:535–546. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Song N, Liu B, Wu JL, Zhang RF, Duan L, He
WS and Zhang CM: Prognostic value of HMGB3 expression in patients
with non-small cell lung cancer. Tumour Biol. 34:2599–2603. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Barreiro-Alonso A, Lamas-Maceiras M,
Rodriguez-Belmonte E, Vizoso-Vázquez Á, Quindós M and Cerdán ME:
High mobility group B proteins, their partners, and other redox
sensors in ovarian and prostate cancer. Oxid Med Cell Longev.
2016:58450612016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Reeves R: High mobility group (HMG)
proteins: Modulators of chromatin structure and DNA repair in
mammalian cells. DNA Repair (Amst). 36:122–136. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Oka T, Sasakawa T, Komori N, Miyamoto K,
Suzuki I, Sassa T and Natori Y: Developmental changes in the
expression of HMG 2a protein. FEBS Lett. 316:20–22. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Oka T, Endo Y, Ito M, Miyamoto K, Sasakawa
T, Suzuki I and Natori Y: Molecular cloning of chick liver HMG 2a
cDNA and developmental expression of HMG 2a mRNA. Biochim Biophys
Acta. 1130:224–226. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gordon JS, Rosenfeld BI, Kaufman R and
Williams DL: Evidence for a quantitative tissue-specific
distribution of high mobility group chromosomal proteins.
Biochemistry. 19:4395–4402. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nemeth MJ, Kirby MR and Bodine DM: Hmgb3
regulates the balance between hematopoietic stem cell self-renewal
and differentiation. Proc Natl Acad Sci USA. 103:13783–13788. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nemeth MJ, Cline AP, Anderson SM,
Garrett-Beal LJ and Bodine DM: Hmgb3 deficiency deregulates
proliferation and differentiation of common lymphoid and myeloid
progenitors. Blood. 105:627–634. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nemeth MJ, Curtis DJ, Kirby MR,
Garrett-Beal LJ, Seidel NE, Cline AP and Bodine DM: Hmgb3: An
HMG-box family member expressed in primitive hematopoietic cells
that inhibits myeloid and B-cell differentiation. Blood.
102:1298–1306. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cai X, Ding H, Liu Y, Pan G, Li Q, Yang Z
and Liu W: Expression of HMGB2 indicates worse survival of patients
and is required for the maintenance of Warburg effect in pancreatic
can. Acta Biochim Biophys Sin (Shanghai). 49:119–127.
2017.PubMed/NCBI
|
|
15
|
Yu JW, Mai W, Cui YL and Kong LY: Genes
and pathways identified in thyroid carcinoma based on
bioinformatics analysis. Neoplasma. 63:559–568. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guo S, Wang Y, Gao Y, Zhang Y, Chen M, Xu
M, Hu L, Jing Y, Jing F, Li C, et al: Knockdown of high mobility
group-box 3 (HMGB3) expression inhibits proliferation, reduces
migration, and affects chemosensitivity in gastric cancer cells.
Med Sci Monit. 22:3951–3960. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li M, Cai Y, Zhao H, Xu Z, Sun Q, Luo M,
Gu L, Meng M, Han X and Sun H: Overexpression of HMGB3 protein
promotes cell proliferation, migration and is associated with poor
prognosis in urinary bladder cancer patients. Tumour Biol.
36:4785–4792. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gao J, Zou Z, Gao J, Zhang H, Lin Z, Zhang
Y, Luo X, Liu C, Xie J and Cai C: Increased expression of HMGB3: A
novel independent prognostic marker of worse outcome in patients
with esophageal squamous cell carcinoma. Int J Clin Exp Pathol.
8:345–352. 2015.PubMed/NCBI
|
|
19
|
Elgamal OA, Park JK, Gusev Y,
Azevedo-Pouly AC, Jiang J, Roopra A and Schmittgen TD: Tumor
suppressive function of mir-205 in breast cancer is linked to HMGB3
regulation. PLoS One. 8:e764022013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak K J and Schmittgen T D: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Szklarczyk D, Morris JH, Cook H, Kuhn M,
Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al:
The STRING database in 2017: Quality-controlled protein-protein
association networks, made broadly accessible. Nucleic Acids Res.
45((D1)): D362–D368. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xian L, Huso T, Belton A, Huso D and Resar
LM: High mobility group A1 chromatin remodeling protein expands the
intestinal stem cell compartment and Paneth cell niche through
Wnt/β-catenin signaling and Sox9. Am Assoc Cancer Res. 76:16–20.
2016.
|
|
23
|
Wu T, Zhang W, Yang G, Li H, Chen Q, Song
R and Zhao L: HMGB1 overexpression as a prognostic factor for
survival in cancer: A meta-analysis and systematic review.
Oncotarget. 7:50417–50427. 2016.PubMed/NCBI
|
|
24
|
Sumter TF, Xian L, Huso T, Koo M, Chang
YT, Almasri TN, Chia L, Inglis C, Reid D and Resar LM: The high
mobility group A1 (HMGA1) transcriptome in cancer and development.
Curr Mol Med. 16:353–393. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Resar L, Xian L, Huso T, Belton A, Cope L
and Huso D: High mobility group A1 chromatin remodeling protein
regulates self-renewal, niche formation and regenerative function
in adult stem cells through wnt/β-catenin signaling. Am Soc
Hematol. 128:26472016.
|
|
26
|
Kalomoiris S, Cicchetto AC, Lakatos K,
Nolta JA and Fierro FA: Fibroblast growth factor 2 regulates high
mobility group A2 expression in human bone marrow-derived
mesenchymal stem cells. J Cell Biochem. 117:2128–2137. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pallante P, Sepe R, Puca F and Fusco A:
High mobility group a proteins as tumor markers. Front Med
(Lausanne). 2:152015.PubMed/NCBI
|
|
28
|
Hayakawa K, Pham LD, Arai K and Lo EH:
High-mobility group box 1: An amplifier of stem and progenitor cell
activity after stroke. Acta Neurochir Suppl. 118:31–38.
2013.PubMed/NCBI
|
|
29
|
Stros M: HMGB proteins: Interactions with
DNA and chromatin. Biochim Biophys Acta. 1799:101–113. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rafehi H, Orlowski C, Georgiadis GT,
Ververis K, El-Osta A and Karagiannis TC: Clonogenic assay:
Adherent cells. J Vis Exp. pii:25732011.
|
|
31
|
Lee EY and Muller WJ: Oncogenes and tumor
suppressor genes. Cold Spring Harb Perspect Biol. 2:a0032362010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Postnikov YV and Bustin M: Functional
interplay between histone H1 and HMG proteins in chromatin. Biochim
Biophys Acta. 1859:462–467. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Stros M, Launholt D and Grasser KD: The
HMG-box: A versatile protein domain occurring in a wide variety of
DNA-binding proteins. Cell Mol Life Sci. 64:2590–2606. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yamada Y, Nishikawa R, Kato M, Okato A,
Arai T, Kojima S, Yamazaki K, Naya Y, Ichikawa T and Seki N:
Regulation of HMGB3 by antitumor miR-205-5p inhibits cancer cell
aggressiveness and is involved in prostate cancer pathogenesis. J
Hum Genet. 63:195–205. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang Z, Chang Y, Zhang J, Lu Y, Zheng L,
Hu Y, Zhang F and Li X, Zhang W and Li X: HMGB3 promotes growth and
migration in colorectal cancer by regulating WNT/β-catenin pathway.
PLoS One. 12:e01797412017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Garcia H, Miecznikowski JC, Safina A,
Commane M, Ruusulehto A, Kilpinen S, Leach RW, Attwood K, Li Y,
Degan S, et al: Facilitates chromatin transcription complex is an
‘accelerator’ of tumor transformation and potential marker and
target of aggressive cancers. Cell Rep. 4:159–173. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dinant C, Ampatziadis-Michailidis G, Lans
H, Tresini M, Lagarou A, Grosbart M, Theil AF, van Cappellen WA,
Kimura H, Bartek J, et al: Enhanced chromatin dynamics by FACT
promotes transcriptional restart after UV-induced DNA damage. Mol
Cell. 51:469–479. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dermawan JK, Hitomi M, Silver DJ, Wu Q,
Sandlesh P, Sloan AE, Purmal AA, Gurova KV, Rich JN, Lathia JD, et
al: Pharmacological targeting of the histone chaperone complex FACT
preferentially eliminates glioblastoma stem cells and prolongs
survival in preclinical models. Cancer Re. 76:2432–2442. 2016.
View Article : Google Scholar
|
